Verrica Pharmaceuticals Inc. (VRCA) Revenue History
Annual and quarterly revenue from 2016 to present
VRCA Revenue Over Time (2016–2025)
VRCA Revenue Growth History
2 of 4 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -24.7%
- FY2023 revenue growth
- -43.3%
- FY2024 revenue growth
- +47.7%
- FY2025 revenue growth
- +370.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $5.0M | +46.1% |
| Q4 2025 | $5.1M | +1380.2% |
| Q3 2025 | $14.3M | +905.4% |
| Q2 2025 | $12.7M | +145.4% |
| Q1 2025 | $3.4M | -10.1% |
| Q4 2024 | $344K | -82.7% |
| Q3 2024 | $-1,781,000 | -161.1% |
| Q2 2024 | $5.2M | +2744.5% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
VRCA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
VRCA Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 28, 2026, Verrica Pharmaceuticals Inc. (VRCA) generated trailing twelve-month (TTM) revenue of $37.2 million, reflecting explosive growth of +46.1% year-over-year. The most recent quarter (Q1 2026) recorded $5.0 million in revenue, down 1.4% sequentially.
Historical Growth Trajectory
VRCA's historical revenue data shows a 3-year CAGR of +57.9%. Verrica Pharmaceuticals Inc.'s highest annual revenue of $35.6 million was recorded in 2025, an all-time high.
Revenue by Segment
VRCA's revenue is primarily driven by License And Collaboration Revenue (57%), and Product (43%). With over half of revenue concentrated in License And Collaboration Revenue, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including DERM (+15.0% YoY), PRGO (-3.6% YoY), and NVCR (+8.5% YoY) — VRCA has outperformed the peer group in revenue growth. Compare VRCA vs DERM →
VRCA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VRCACurrent | $37M | +46.1% | - | -33.6% | |
 DERM | $62M | +15.0% | +6.8% | -13.2% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 SKIN | $301M | -8.2% | +20.4% | -6.9% | |
 GDRX | $797M | -1.2% | +7.7% | 11.0% |
VRCA Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $35.6M | +370.2% | $32.1M | 90.3% | $-11,939,000 | -33.6% |
| 2024 | $7.6M | +47.7% | $4.8M | 63.8% | $-65,919,000 | -871.3% |
| 2023 | $5.1M | -43.3% | $4.4M | 85.4% | $-65,759,000 | -1283.4% |
| 2022 | $9.0M | -24.7% | $8.3M | 92.0% | $-21,296,000 | -235.8% |
| 2021 | $12.0M | - | $11.5M | 96.1% | $-30,908,000 | -257.6% |
| 2020 | $0 | - | $-229,000 | - | $-40,181,000 | - |
| 2019 | $0 | - | $-257,199 | - | $-30,080,000 | - |
| 2018 | $0 | - | $-20,294 | - | $-21,878,000 | - |
| 2017 | $0 | - | $0 | - | $-4,457,000 | - |
| 2016 | $0 | - | $0 | - | $-1,913,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VRCA — Frequently Asked Questions
Quick answers to the most common questions about buying VRCA stock.
Is VRCA's revenue growth accelerating or slowing?
VRCA revenue growth is accelerating. TTM revenue reached $37M, up +46.1% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is VRCA's revenue history from 2016 to 2026?
Verrica Pharmaceuticals Inc. (VRCA) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $37M, growing at +46.1% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is VRCA's long-term revenue growth rate (CAGR)?
Verrica Pharmaceuticals Inc.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +46.1% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for VRCA.
Why does VRCA's quarterly revenue fluctuate?
VRCA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Verrica Pharmaceuticals Inc.'s revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is VRCA's revenue distributed by segment?
VRCA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does VRCA's revenue compare to industry peers?
Verrica Pharmaceuticals Inc. (VRCA) with TTM revenue of $37M and +46.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.